Unicycive Therapeutics (UNCY) Other Accumulated Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Other Accumulated Expenses data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 1032.19% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 1032.19% YoY) and the FY2025 annual result came in at $82000.0, down 79.19% from the prior year.
• Other Accumulated Expenses rose to $1.7 million in Q1 2026, from $82000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q1 2026 to a low of $67000.0 in Q2 2025.
• A 5-year average of $389923.1 and a median of $283000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses slumped 79.19% — and 2026, when it soared 1032.19%.
• Tracing UNCY's Other Accumulated Expenses over 5 years: stood at $522000.0 in 2022, then slumped by 45.79% to $283000.0 in 2023, then soared by 39.22% to $394000.0 in 2024, then plunged by 79.19% to $82000.0 in 2025, then surged by 1915.85% to $1.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.7 million (Q1 2026), $82000.0 (Q4 2025), and $406000.0 (Q3 2025), per Business Quant data.